Abstract
| Medication adherence in inflammatory bowel disease Chan W1,2, Chen A3, Tiao D4, Selinger C5, Leong R1. Intest Res. 2017 Oct;15(4):434-445. doi: 10.5217/ir.2017.15.4.434. Epub 2017 Oct 23. |
| Author information 1 Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia. 2 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore. 3 South Western Sydney Clinical School, University of New South Wales, Australia. 4 Sydney Medical School, the University of Sydney, Sydney, Australia. 5 IBD Unit, Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds, UK. Abstract Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition with intestinal and extraintestinal manifestations. Medications are the cornerstone of treatment of IBD. However, patients often adhere to medication poorly. Adherence to medications is defined as the process by which patients take their medications as prescribed. Treatment non-adherence is a common problem among chronic diseases, averaging 50% in developed countries and is even poorer in developing countries. In this review, we will examine the adherence data in IBD which vary greatly depending on the study population, route of administration, and methods of adherence measurement used. We will also discuss the adverse clinical outcomes related to non-adherence to medical treatment including increased disease activity, flares, loss of response to anti-tumor necrosis factor therapy, and so forth. There are many methods to measure medication adherence namely direct and indirect methods, each with their advantages and drawbacks. Finally, we will explore different intervention strategies to improve adherence to medications. |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.
